JNJ-53718678
Sponsors
Janssen Sciences Ireland UC, Janssen Research & Development, LLC
Conditions
HealthyHepatic ImpairmentRespiratory Syncytial VirusRespiratory Syncytial Virus InfectionsVirus Diseases
Phase 1
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
TerminatedNCT02593851
Start: 2015-12-04End: 2017-11-10Updated: 2019-12-06
A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults
CompletedNCT02729467
Start: 2016-03-31End: 2016-06-30Updated: 2025-02-03
A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation
CompletedNCT02945007
Start: 2016-11-08End: 2020-01-16Updated: 2020-03-10
A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants
CompletedNCT03002779
Start: 2017-01-26End: 2017-03-20Updated: 2017-05-31
A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants
CompletedNCT04090086
Start: 2019-09-16End: 2019-12-10Updated: 2025-02-03
A Study of JNJ-53718678 in Participants With Hepatic Impairment
TerminatedNCT04332523
Start: 2020-08-17End: 2022-03-16Updated: 2022-06-13
Phase 2
Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.
CompletedNCT02387606
Start: 2015-05-07End: 2015-10-02Updated: 2022-10-26
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
TerminatedNCT03656510
Start: 2018-11-29End: 2022-04-18Updated: 2025-02-04